Insmed (INSM) Q1 2024 Earnings
INSM·Reported May 9, 2024·Before market open
Insmed reported Q1 2024 revenue of $75.5M, missed analyst consensus of $77.8M by $2.3M. Diluted EPS came in at $-1.06, beat the $-1.24 consensus by $0.18. Insmed reports across 3 business segments, led by Respiratory, Immunology & Inflammation, and Neuro & Other Rare.
Revenue
$75.5Mmissed by $2.3M
Consensus: $77.8MDiluted EPS
$-1.06beat by $0.18
Consensus: $-1.24
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Insmed's Q1 2024 earnings report.
Insmed (INSM) reported Q1 2024 earnings on May 9, 2024 before market open.
Insmed reported revenue of $75.5M and diluted EPS of $-1.06 for Q1 2024.
Revenue missed the consensus estimate of $77.8M by $2.3M. EPS beat the consensus estimate of $-1.24 by $0.18.
You can read the 10-Q periodic report (0001104506-24-000016) directly on SEC EDGAR. The filing index links above go to sec.gov.